• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Novel RET Fusion Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma.

作者信息

Mweempwa Angela, Xu Huiling, Vissers Joseph H A, Tothill Richard W, Pattison Andrew D, Fellowes Andrew P, Thomas David M, Richardson Gary, Hicks Rodney J, Grimmond Sean M, Fox Stephen B, Luen Stephen J, Desai Jayesh, Solomon Benjamin J

机构信息

Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

出版信息

JCO Precis Oncol. 2021 Nov;5:1160-1165. doi: 10.1200/PO.21.00127.

DOI:10.1200/PO.21.00127
PMID:34994633
Abstract
摘要

相似文献

1
Novel RET Fusion Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma.新型RET融合预测恶性嗜铬细胞瘤对塞普替尼选择性RET抑制的反应。
JCO Precis Oncol. 2021 Nov;5:1160-1165. doi: 10.1200/PO.21.00127.
2
Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With Fusion-Positive Breast Cancer.一名融合阳性乳腺癌患者对塞尔帕替尼（LOXO-292）选择性RET抑制的完全缓解。
JCO Precis Oncol. 2021 Jan 11;5. doi: 10.1200/PO.20.00282. eCollection 2021.
3
Response to the Selective RET Inhibitor Selpercatinib (LOXO-292) in a Patient With RET Fusion-positive Atypical Lung Carcinoid.RET融合阳性非典型肺类癌患者对选择性RET抑制剂塞尔帕替尼（LOXO-292）的反应
Clin Lung Cancer. 2021 May;22(3):e442-e445. doi: 10.1016/j.cllc.2020.06.011. Epub 2020 Jun 18.
4
Selpercatinib.塞尔帕替尼
Am J Health Syst Pharm. 2020 Oct 30;77(22):1818-1821. doi: 10.1093/ajhp/zxaa279.
5
Rearranged-in-transfection inhibitors: emerging agnostic targeted therapies for solid tumors.转染重排抑制剂：实体瘤新兴的非特异性靶向治疗方法
Pharmacogenomics. 2021 Apr;22(5):247-250. doi: 10.2217/pgs-2021-0002. Epub 2021 Mar 23.
6
Selpercatinib: First Approval.塞尔帕替尼：首次批准。
Drugs. 2020 Jul;80(11):1119-1124. doi: 10.1007/s40265-020-01343-7.
7
Successful combination of selpercatinib and radioiodine after pretherapeutic dose estimation in RET-altered thyroid carcinoma.在RET改变的甲状腺癌中进行治疗前剂量估计后，塞普替尼与放射性碘的成功联合应用。
Eur J Nucl Med Mol Imaging. 2023 May;50(6):1833-1834. doi: 10.1007/s00259-022-06061-8. Epub 2022 Dec 16.
8
Efficacy of Selpercatinib in Fusion-Positive Non-Small-Cell Lung Cancer.塞尔帕替尼治疗融合阳性非小细胞肺癌的疗效
N Engl J Med. 2020 Aug 27;383(9):813-824. doi: 10.1056/NEJMoa2005653.
9
Erectile Dysfunction in Patients Treated with Selpercatinib for -Altered Thyroid Cancer.接受塞尔帕替尼治疗的甲状腺癌患者的勃起功能障碍
Thyroid. 2024 Sep;34(9):1177-1180. doi: 10.1089/thy.2024.0129. Epub 2024 Jul 19.
10
RET fusions in non-small-cell lung cancer: an emerging target reshaping the treatment paradigm.非小细胞肺癌中的RET融合：重塑治疗模式的新兴靶点
Future Oncol. 2021 Apr;17(12):1445-1448. doi: 10.2217/fon-2020-1297. Epub 2021 Feb 12.

引用本文的文献

1
Inhibitory Effects of Vandetanib on Catecholamine Synthesis in Rat Pheochromocytoma PC12 Cells.凡德他尼对大鼠嗜铬细胞瘤PC12细胞儿茶酚胺合成的抑制作用
Int J Mol Sci. 2025 Jul 18;26(14):6927. doi: 10.3390/ijms26146927.
2
Pheochromocytoma in MEN2.多发性内分泌腺瘤病2型中的嗜铬细胞瘤
Recent Results Cancer Res. 2025;223:211-235. doi: 10.1007/978-3-031-80396-3_8.
3
What Is New in Diagnostics and Management of Medullary Thyroid Carcinoma.甲状腺髓样癌诊断与管理的新进展
Recent Results Cancer Res. 2025;223:1-8. doi: 10.1007/978-3-031-80396-3_1.
4
Clinical Activity of Selpercatinib in RET-mutant Pheochromocytoma.塞尔帕替尼在RET突变型嗜铬细胞瘤中的临床活性
J Clin Endocrinol Metab. 2025 Feb 18;110(3):e600-e606. doi: 10.1210/clinem/dgae283.
5
Current prospects of hereditary adrenal tumors: towards better clinical management.遗传性肾上腺肿瘤的当前前景：迈向更好的临床管理
Hered Cancer Clin Pract. 2024 Mar 26;22(1):4. doi: 10.1186/s13053-024-00276-6.
6
-Altered Cancers-A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy Activity.- 改变的癌症——肿瘤非特异性生物学、诊断及靶向治疗活性综述
Cancers (Basel). 2023 Aug 17;15(16):4146. doi: 10.3390/cancers15164146.
7
Update on the genetics of paragangliomas.关于副神经节瘤遗传学的最新进展。
Endocr Relat Cancer. 2023 Mar 8;30(4). doi: 10.1530/ERC-22-0373. Print 2023 Apr 1.
8
Targeted Therapies in Pheochromocytoma and Paraganglioma.靶向治疗在嗜铬细胞瘤和副神经节瘤中的应用。
J Clin Endocrinol Metab. 2022 Nov 23;107(11):2963-2972. doi: 10.1210/clinem/dgac471.
9
Pediatric Metastatic Pheochromocytoma and Paraganglioma: Clinical Presentation and Diagnosis, Genetics, and Therapeutic Approaches.小儿转移性嗜铬细胞瘤和副神经节瘤：临床表现和诊断、遗传学和治疗方法。
Front Endocrinol (Lausanne). 2022 Jul 12;13:936178. doi: 10.3389/fendo.2022.936178. eCollection 2022.
10
A RET::GRB2 fusion in pheochromocytoma defies the classic paradigm of RET oncogenic fusions.在嗜铬细胞瘤中发现的 RET::GRB2 融合打破了经典的 RET 致癌融合范例。
Cell Rep Med. 2022 Jul 19;3(7):100686. doi: 10.1016/j.xcrm.2022.100686.